Synlogic, Inc (SYBX)

Etorro trading 970x250
Synlogic, Inc (SYBX) Logo

About Synlogic, Inc

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts. Address: 301 Binney Street, Cambridge, MA, United States, 02142

Synlogic, Inc News and around…

Latest news about Synlogic, Inc (SYBX) common stock and company :

Benzinga's Top Ratings Upgrades, Downgrades For November 24, 2021
24 Nov, 2021 FinancialContent

Upgrades For Aegon NV (NYSE:AEG), Credit Suisse upgraded the previous rating of Neutral to Outperform. At the moment, ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
24 Nov, 2021 FinancialContent

Gainers Ocuphire Pharma (NASDAQ:OCUP) stock rose 78.73% to $6.22 during Wednesday's pre-market session. The market ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
24 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting the last day of this short holiday week with a dive into the biggest pre-market stock movers for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
23 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive ...

Synlogic Presents Data Demonstrating Reductions in Plasma Phenylalanine Levels in Patients with Phenylketonuria Treated with SYNB1618
23 Nov, 2021 Yahoo! Finance

Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today announced presentation of interim data from the company's Phase 2 SynPheny-1 clinical trial showing that treatment with the investigational Synthetic BioticTM medicine SYNB1618 resulted in significant reductions in plasma phenylalanine (Phe) levels in patients with phenylketonuria (PKU). Results were presented today by Dr. Jerry Vockley, MD, PhD in a late-breaking

The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
21 Nov, 2021 FinancialContent

Biotech stocks showed a lack of direction in the week endingNov. 19 before finishing modestly higher. Stocks did not have much ...

AbbVie's (ABBV) Skyrizi Gets Nod for Psoriatic Arthritis in EU
18 Nov, 2021 Yahoo! Finance

AbbVie (ABBV) secures approval in the EU for Skyrizi to treat adult patients with active psoriatic arthritis.

Novavax (NVAX) COVID Jab Gets Philippines Nod, Under Review in EU
18 Nov, 2021 Yahoo! Finance

Novavax's (NVAX) secures approval for its COVID vaccine in the Philippines. The EMA begins reviewing the company's regulatory submission for its COVID vaccine. Evidently, the stock gains.

CRISPR (CRSP) to Begin Clinical Study on Diabetes Therapy Drug
17 Nov, 2021 Yahoo! Finance

CRISPR Therapeutics (CRSP) receives clearance from Health Canada to initiate clinical studies for VCTX210, its investigational therapy for the treatment of type 1 diabetes.

Synlogic (NASDAQ:SYBX) shareholders have endured a 69% loss from investing in the stock three years ago
12 Nov, 2021 Yahoo! Finance

Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...

Synlogic's Return On Capital Employed Insights
11 Nov, 2021 FinancialContent

Synlogic (NASDAQ:SYBX) brought in sales totaling $916.00 thousand during Q3 according to data provided by Benzinga Pro. However, ...

Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates
10 Nov, 2021 Yahoo! Finance

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 0.00% and 233.09%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Synlogic Announces Presentation of Phenylketonuria Data at 14th International Congress of Inborn Errors of Metabolism Meeting
10 Nov, 2021 Yahoo! Finance

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced presentation of new data from the company's clinical development program for phenylketonuria (PKU) during the 14th International Congress of Inborn Errors of Metabolism Meeting being held in Sydney, Australia November 21-24, 2021.

Synlogic Reports Third Quarter Financial Results and Provides Business Update
10 Nov, 2021 Yahoo! Finance

Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the third quarter ended September 30, 2021 and provided an update on clinical programs.

Synlogic and Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria
09 Nov, 2021 Yahoo! Finance

Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the nomination of SYNB1353, an investigational Synthetic BioticTM medicine for the treatment of homocystinuria (HCU). SYNB1353 is the first product developed through a research collaboration between Synlogic and Ginkgo and the first investigational medicine developed o

Synlogic Announces Third Quarter 2021 Conference Call & Participation in Upcoming Banking Conference
02 Nov, 2021 Yahoo! Finance

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its third quarter 2021 financial results before the market opens on Wednesday, November 10, 2021. The press release will be followed by a conference call at 8:30 am ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate upda

Synlogic Announces Nature Communications Publication Highlighting Use of Synthetic Biotic Platform to Optimize Therapies for Phenylketonuria
28 Oct, 2021 Yahoo! Finance

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced a publication in Nature Communications documenting the engineering of a more potent phenylalanine (Phe)-degrading investigational Synthetic Biotic™ medicine for the treatment of phenylketonuria (PKU).

Synlogic Presents Data on Hyperoxaluria Program at American Society of Nephrology Kidney Week 2021
15 Oct, 2021 Yahoo! Finance

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced two poster presentations at the upcoming American Society for Nephrology (ASN) Kidney Week 2021, to be held virtually November 4 – 7th, 2021.

Synlogic Announces Nature Publication Demonstrating Novel Application of Synthetic Biotic Platform
12 Oct, 2021 Yahoo! Finance

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the publication in Nature of preclinical research with live biotherapeutic products designed using the Company's Synthetic Biotic™ platform. In the study, a live biotherapeutic product modulated the tumor microenvironment and increased susceptibility to immunotherapy in a murine model. The research was led by Synlogic collaborators and Professor Roger Ge

Dice Therapeutics and Hemisphere Media Stock See Action From Activist Investors
01 Oct, 2021 Yahoo! Finance

RA Capital Management disclosed a large position in Dice Therapeutics. Edenbrook Capital raised its position in Spanish-language media firm Hemisphere Media.

Synlogic Appoints Molly Harper as Chief Business Officer
27 Sep, 2021 Yahoo! Finance

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Molly Harper as Chief Business Officer. Ms. Harper will provide strategic leadership to the commercial, corporate development and business development functions, and lead the planning and commercialization of Synlogic's growing pipeline.

12 Health Care Stocks Moving In Thursday's Pre-Market Session
23 Sep, 2021 FinancialContent

Gainers TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 23.66% to $3.24 during Thursday's pre-market ...

The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
23 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
23 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We're diving back into the stock market again today with a look at the biggest pre-market stock movers for Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

24 Stocks Moving in Thursday's Pre-Market Session
23 Sep, 2021 FinancialContent

Gainers Amplitude Healthcare Acquisition Corporation (NASDAQ: AMHC) rose 61.8% to $16.55 in pre-market trading. The company ...

Synlogic Announces Pricing of Public Offering of Common Stock
23 Sep, 2021 Yahoo! Finance

Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $3.00 per share. The gross proceeds to Synlogic from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Synlogic, are expected to be $45.0 million. All shares of common stock to be sold in

12 Health Care Stocks Moving In Wednesday's After-Market Session
22 Sep, 2021 FinancialContent

Gainers Regencell Bioscience (NASDAQ:RGC) shares rose 21.54% to $25.1 during Wednesday's after-market session. ...

Synlogic Announces Proposed Public Offering of Common Stock
22 Sep, 2021 Yahoo! Finance

Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Synlogic. Synlogic intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to

48 Biggest Movers From Yesterday
21 Sep, 2021 FinancialContent

Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 ...

Mid-Afternoon Market Update: Dow Tumbles 2.5%; BeyondSpring Shares Plunge
20 Sep, 2021 FinancialContent

Toward the end of trading Monday, the Dow traded down 2.57% to 33,696.98 while the NASDAQ fell 3.14% to 14,572.25. The S&P also ...

Synlogic, Inc (SYBX) is a NASDAQ Common Stock listed in , ,

970x250